SCHEDULE 13G/A: Avenir Corp and James H. Rooney Disclose 5.66% Stake in Cytosorbents Corp

Avenir Corporation and James H. Rooney have disclosed a shared beneficial ownership of 5.66% of Cytosorbents Corp's common stock as of December 31, 2024.

Summary

• Avenir Corporation, a Virginia-based investment adviser, and James H. Rooney, its portfolio manager and shareholder, have filed an Amendment No. 3 to Schedule 13G.
• The filing reports their shared beneficial ownership of 3,093,946 shares of Cytosorbents Corp's common stock.
• This stake represents 5.66% of the issuer's common stock.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cytosorbents Corp.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive investment by an institutional entity, which can be seen as a positive signal of confidence in the company. There are no negative operational details about the company itself within this filing.

Positives

• A significant institutional investor, Avenir Corporation, and its portfolio manager, James H. Rooney, have taken a substantial stake in Cytosorbents Corp, indicating potential confidence in the company's long-term prospects.
• The filing explicitly states the shares were acquired in the ordinary course of business and not for control, suggesting a passive investment strategy.

Future Outlook

The document does not provide any forward-looking statements or guidance from Cytosorbents Corp or the reporting persons regarding the issuer's future.

Management Comments

• James H. Rooney, on behalf of Avenir Corp and himself, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates an investment firm's position in a biotechnology or medical device company (Cytosorbents Corp is known for blood purification technologies). Such disclosures are common for institutional investors taking significant, passive stakes in public companies.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for investors acquiring more than 5% of a company's stock. It does not provide information for comparing Cytosorbents Corp's performance to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake might be viewed positively, potentially increasing investor confidence.

Key Dates

Keywords

Cytosorbents Corp, CYTX, Avenir Corp, James H. Rooney, Schedule 13G, beneficial ownership, institutional investment, common stock, SEC filing